Nobel Prize in Physiology or Medicine 2018
The 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo “for their discovery of cancer therapy by inhibition of negative immune regulation”. Their pioneering work on the CTLA4 and PD1 immune checkpoints revealed that these pathways act as so-called ‘brakes’ on the immune system, and showed that inhibition of these checkpoint pathways allows T cells to more effectively eradicate cancer cells. This research laid the foundation for the clinical development of immune checkpoint inhibitors, which have dramatically improved outcomes for many people with cancer.
This Collection presents research, review, news and comment articles from Nature Research to celebrate the award. The collection content is editorially independent and the sole responsibility of Springer Nature.
-
Produced with support from:
-
-
Funded by a grant from:
Selected content is made freely available for 6 months (until April 2019), thanks to the financial support of Bristol-Myers Squibb and GlaxoSmithKline. Additional funding was provided by a grant from Merck & Co., Inc., Kenilworth, New Jersey. The sponsors retain sole responsibility for the following messages.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
